
October 18, 2014	Web Version \| Share with a colleague \| eNews Subscribe	You are subscribed to the FormularyWatch eNews

FDA's new hep C approval: A step closer to a cure?

FDA's approval of ledipasvir 90 mg/sofosbuvir 400 mg (Harvoni, Gilead Sciences), the first once-daily single tablet regimen for the treatment of chronic hepatitis C genotype 1 infection in adults, may signal that industry is at the forefront of a cure for hepatitis C, according to one industry expert. » Read more about Harvoni

FDA approves bortezomib for injection for previously untreated patients with mantle cell lymphoma

FDA approved bortezomib (Velcade, Millennium: The Takeda Oncology Company) for injection for use in previously untreated patients with mantle cell lymphoma (MCL). » Read about Velcade's extended use

#icymi